Literature DB >> 22190445

Surmounting chemoresistance by targeting the Y-box binding protein-1.

Ikuyo Inoue1, Ken Matsumoto, Yingnan Yu, Boon-Huat Bay.   

Abstract

The Y-box binding protein 1 (YB-1), characterized by the presence of the cold shock domain, has been reported to induce chemoresistance in cancer therapy. Chemotherapy is one of the main therapeutic strategies in the treatment of cancer, in addition to surgery, radiation therapy, and hormonal therapy. However, chemoresistance remains a key obstacle to successful cancer management. In this review, we will focus on the role of YB-1, an important regulator of gene transcription, in cancer therapy and chemoresistance.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190445     DOI: 10.1002/ar.22401

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  3 in total

1.  Elevated mRNA Level of Y-Box Binding Protein 1 Indicates Unfavorable Prognosis Correlated with Macrophage Infiltration and T Cell Exhaustion in Luminal Breast Cancer.

Authors:  Zhenhuan Lv; Chunli Xue; Lei Zhang; Jujie Sun; Cong Bo
Journal:  Cancer Manag Res       Date:  2021-08-14       Impact factor: 3.989

2.  YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.

Authors:  Jia Pei Lim; Sukanya Shyamasundar; Jayantha Gunaratne; Olivia Jane Scully; Ken Matsumoto; Boon Huat Bay
Journal:  BMC Cancer       Date:  2017-03-16       Impact factor: 4.430

Review 3.  Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

Authors:  Sarah Blagden; Mai Abdel Mouti; James Chettle
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-01       Impact factor: 9.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.